- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01602757
Pharmacokinetic Study of Synera in Healthy Volunteers
October 15, 2012 updated by: ZARS Pharma Inc.
An Open-Label Pharmacokinetic Study of the Synera Patch Applied for 2-, 4-, and 12-hours and a Lidocaine/Tetracaine Patch Without Heat Applied for 4 Hours in Healthy Adult Volunteers
This study will measure the amount of lidocaine and tetracaine in the blood after 2-, 4-, and 12-hour application of 4 Synera patches and a 4 hour application of 4 patches without heat.
Study Overview
Detailed Description
The purpose of this study was to evaluate the pharmacokinetic profiles of lidocaine and tetracaine after 2-, 4-, and 12-hour application of 4 Synera® patches and a 4-hour application of 4 lidocaine/tetracaine patches without heat in healthy adult subjects and to monitor the frequency and nature of adverse events.
In addition to determining the pharmacokinetics for a one-time application of 4 Synera® patches, steady-state pharmacokinetics were modeled and residual patch concentrations of lidocaine and tetracaine were determined.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Dakota
-
Fargo, North Dakota, United States, 58104
- Cetero Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- be at least 18 years of age
- be a nonsmoker
- have a body mass index (BMI) ≥ 18.5 and < 30.0
Exclusion Criteria:
- known or suspected hypersensitivity, allergies, or other contraindications to any compound present in the study drug, including lidocaine, tetracaine, or other local anesthetics.
- have a defect, injury or a dermatological disease or condition in the skin area where the study drug was to be applied.
- have a history or current evidence of any hepatic impairment.
- have failed the urine drug screen.
- have used or been administered a local or systemic anesthetic, including over-the-counter products, within the past 14 days.
- have donated blood or plasma within the past 30 days.
- have participated in a clinical research study within the past 30 days.
- are pregnant, breastfeeding, or was a female of childbearing potential and not practicing adequate birth control
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Synera
Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4.
During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat ("no heat patches") and were crossed over during Study Session 3.
|
Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4.
During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat ("no heat patches") and were crossed over during Study Session 3.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak plasma concentration (Cmax) of Synera after application of 4 patches
Time Frame: 0.5, 1, 1.5, 2, 4, 8, 10, 12 hours post-dose
|
Peak plasma concentration of Synera after application of 4 patches for 2-, 4- and 12-hours
|
0.5, 1, 1.5, 2, 4, 8, 10, 12 hours post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events
Time Frame: 24 days
|
24 days
|
|
Area under the plasma concentration versus time (AUC) of Synera
Time Frame: 0.5, 1, 1.5, 2, 4, 8, 10, 12 hours post-dose
|
Area under the plasma concentration versus time curve of Synera after application of 4 patches for 2-, 4-, and 12 hours
|
0.5, 1, 1.5, 2, 4, 8, 10, 12 hours post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Anthony R Godfrey, Pharm.D., Cetero Research, San Antonio
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2010
Primary Completion (Actual)
March 1, 2010
Study Completion (Actual)
March 1, 2010
Study Registration Dates
First Submitted
May 15, 2012
First Submitted That Met QC Criteria
May 17, 2012
First Posted (Estimate)
May 21, 2012
Study Record Updates
Last Update Posted (Estimate)
October 17, 2012
Last Update Submitted That Met QC Criteria
October 15, 2012
Last Verified
October 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Lidocaine
- Tetracaine
Other Study ID Numbers
- SC-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Synera
-
Brown, Theodore R., M.D., MPHCompletedMultiple SclerosisUnited States
-
International Clinical Research InstituteCompletedEpicondylitis of the ElbowUnited States
-
Northwell HealthWithdrawnPain | AnxietyUnited States
-
IWK Health CentreDuke UniversityCompleted
-
US Oncology ResearchNuvo Research Inc.Completed
-
University of California, DavisCareDxRecruitingCOVID-19 | Immunosuppression | Vaccine Response ImpairedUnited States
-
Carol MorrealeCompletedPain | Anesthetics, Local | VenipunctureUnited States
-
Columbia UniversityPfizer; Cornell UniversityCompleted
-
Stony Brook UniversityCompleted
-
ZARS Pharma Inc.CompletedMyofascial Pain SyndromesUnited States